Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physostigmine is a naturally occurring alkaloid and a reversible cholinesterase inhibitor derived from the Calabar bean. It acts as a parasympathomimetic agent by inhibiting acetylcholinesterase, the enzyme responsible for breaking down acetylcholine. This inhibition increases acetylcholine concentrations at synapses, thereby stimulating both muscarinic and nicotinic receptors throughout the body. Unlike some other anticholinesterases (e.g., neostigmine), physostigmine is a tertiary amine and can cross the blood-brain barrier, making it effective for reversing both central and peripheral effects of anticholinergic toxicity. Clinically, it is used as an antidote to treat anticholinergic poisoning (such as overdoses of atropine, scopolamine, belladonna alkaloids, antihistamines, certain antidepressants), in addition to its historical use in glaucoma therapy. Its poor tolerability has limited its use in chronic conditions like Alzheimer's disease[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on physostigmine.